---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-122784"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:58:47.130691+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# KalVista reports $49.1M EKTERLY revenue in 8mo transition period, 1,702 patient start forms

## Summary
- Global net product revenue of $49.1M from EKTERLY (sebetralstat) for May–Dec 2025; first commercial sales since launch on July 7, 2025.
- 1,702 patient start forms received in US through Feb 2026, nearly 20% of HAE population; 724 unique prescribers activated.
- R&D expenses $33.4M (down from $52.2M YoY); SG&A $124.7M (up from $64.9M) due to commercialization costs.
- Cash, equivalents and marketable securities $300.2M as of Dec 31, 2025; company expects to fund through profitability.
- Pediatric Phase 3 KONFIDENT-KID trial fully enrolled; interim data to be presented at 2026 Global Angioedema Summit; NDA filing planned Q3 2026.

## SEC filing metadata
- accession: 0001193125-26-122784
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000119312526122784/0001193125-26-122784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000119312526122784/d127514d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-122784
- JSON: https://secwatch.observer/filing/0001193125-26-122784.json
- Plain text: https://secwatch.observer/filing/0001193125-26-122784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.